PF082 VEGFR1, Human, Recombinant, S. frugiperda

PF082
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability

      Overview

      Replacement Information

      Pricing & Availability

      Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
      PF082-50UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 50 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewRecombinant, human VEGFR-1 expressed in S. frugiperda insect cells. Plays an important role in angiogenesis. Upon binding to VEGF, the receptor undergoes dimerization and is activated, leading to downstream signaling.
          Catalogue NumberPF082
          Brand Family Calbiochem®
          SynonymsFlt-1, EMRK2, Vascular Endothelial Growth Factor Receptor-1
          References
          ReferencesHuang, K., et al. 2001. Int. J. Cell Biol. 33, 315.
          Soker, S., et al. 1998. Cell 92, 735.
          Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
          Kendall, R.L. and Thomas, K.A. 1993. PNAS. 90, 10705.
          Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
          Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
          Brown, L., et al. 1992. Kidney International 42, 1457.
          Conn, G., et al. 1990. PNAS 87, 1323.
          Shibuya, M., et al. 1990. Oncogene 5, 519.
          Product Information
          FormLyophilized
          FormulationLyophilized from sterile-filtered PBS, 300 mM NaCl, 50 µg BSA/µg of cytokine.
          Applications
          Data setup Error. Pagelet <collection_feature_application_id-PROLIF> not found.
          Biological Information
          Biological activityEC₅₀ of 15-30 ng/ml in a cell proliferation assay using human umbilical vein endothelial cells
          Purity≥90% by SDS-PAGE
          Species Reactivity
          • Human
          Physicochemical Information
          ContaminantsEndotoxin: ≤1 EU/µg cytokine
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Standard Handling
          Storage -20°C
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          VEGFR1, Human, Recombinant, S. frugiperda SDS

          Title

          Safety Data Sheet (SDS) 

          VEGFR1, Human, Recombinant, S. frugiperda Certificates of Analysis

          TitleLot Number
          PF082

          References

          Reference overview
          Huang, K., et al. 2001. Int. J. Cell Biol. 33, 315.
          Soker, S., et al. 1998. Cell 92, 735.
          Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
          Kendall, R.L. and Thomas, K.A. 1993. PNAS. 90, 10705.
          Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
          Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
          Brown, L., et al. 1992. Kidney International 42, 1457.
          Conn, G., et al. 1990. PNAS 87, 1323.
          Shibuya, M., et al. 1990. Oncogene 5, 519.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision16-September-2008 RFH
          SynonymsFlt-1, EMRK2, Vascular Endothelial Growth Factor Receptor-1
          DescriptionRecombinant, human VEGFR-1 expressed in S. frugiperda insect cells. The disulfide linked dimeric recombinant protein contains two polypeptides of 905 amino acids long with a predicted monomeric molecular mass of ~100 kDa. As a result of glycosylation, the monomer migrates as a ~123 kDa protein in SDS-PAGE. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a secreted heparin binding cytokine expressed in tumor and animal cells. VEGF has been implicated in the control of angiogenesis due to its selective mitogenic stimulation of vascular endothelial cells and enhancement of vascular permeability. VEGF is a ~34-50 kDa dimer of two identical disulfide-linked subunits existing in four molecular species; 121, 165, 189, and 206 amino acid residues long, arising from alternative splicing of a single gene. VEGF binds to two receptor tyrosine kinases, Flt-1 (VEGFR1) and KDR/Flk-1 (VEGFR2) found almost exclusively on human endothelial cells. Flt-1 binds VEGF and a new VEGF-related ligand, placenta growth factor (PIGF) but KDR/Flk-1 binds only VEGF. The cDNA encoding the soluble truncated form of Flt-1 cloned from a human endothelial cell library encodes the 6 N-terminal IgG-like extracellular ligand-binding domain but does not encode the transmembrane spanning region and intracellular tyrosine kinase domains. The recombinant soluble receptor binds avidly to VEGF and is a potent VEGF antagonist. Recently, a third VEGF receptor was identified and cloned from tumor cells. This VEGF receptor is isoform-specific, binding VEGF165 but not VEGF121. Studies indicate that this VEGF receptor (VEGF165R) is identical to human neuropilin-1, a receptor for the collapsin/semaphorin family that mediates neuronal cell guidance.
          Specieshuman
          FormLyophilized
          FormulationLyophilized from sterile-filtered PBS, 300 mM NaCl, 50 µg BSA/µg of cytokine.
          Purity≥90% by SDS-PAGE
          ContaminantsEndotoxin: ≤1 EU/µg cytokine
          Biological activityEC₅₀ of 15-30 ng/ml in a cell proliferation assay using human umbilical vein endothelial cells
          SolubilityReconstitute to ≥10 µg/ml with sterile PBS containing ≥0.1% HSA or BSA. It is recommended that the protein be titrated for optimal results in individual systems.
          Storage -20°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesHuang, K., et al. 2001. Int. J. Cell Biol. 33, 315.
          Soker, S., et al. 1998. Cell 92, 735.
          Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
          Kendall, R.L. and Thomas, K.A. 1993. PNAS. 90, 10705.
          Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
          Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
          Brown, L., et al. 1992. Kidney International 42, 1457.
          Conn, G., et al. 1990. PNAS 87, 1323.
          Shibuya, M., et al. 1990. Oncogene 5, 519.